Acelarin: Phase Ib data

Data from 20 evaluable patients with recurrent platinum-resistant ovarian cancer in the open-label, dose-escalation, U.K. Phase Ib ProGem2 trial showed that Acelarin given on days 1 and 8 every 21 day...